Acrivon Therapeutics (ACRV) Begins U.S. IPO Rollout
seekingalpha.com
news
2022-10-19 15:50:31

FG Trade A Quick Take On Acrivon Therapeutics Acrivon Therapeutics (ACRV) has filed to raise $119 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a clinical stage biopharma developing treatments for ovarian, endometrial and bladder cancers. Notably, the firm's drug candidate also depends on the co-approval of the OncoSignature test as a companion diagnostic test. I'll provide an update when we learn more IPO details from management. Acrivon Overview Watertown, Massachusetts-based Acrivon Therapeutics was founded to develop a platform [AP3] that overcomes various limitations of gene-based patient selection methods, promising to improve patient outcomes.
